<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37529714</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation.</ArticleTitle><Pagination><StartPage>1202696</StartPage><MedlinePgn>1202696</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1202696</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2023.1202696</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Long-COVID is a broadly defined condition and there are no effective therapies. Cardiovascular manifestations of long-COVID include high heart rate, postural tachycardia, and palpitations. Previous studies have suggested that mast cell activation (MCA) may play a role in the pathophysiology of long-COVID, including in the mechanisms of its cardiovascular manifestations. The present study aimed to evaluate the effectiveness of a treatment with blockers of histamine receptors in patients with long-COVID who did not respond to other therapies.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In all, 14 patients (F/M&#x2009;=&#x2009;9/5; 49.5&#x2009;&#xb1;&#x2009;11.5 years) and 13 controls (F/M&#x2009;=&#x2009;8/5; 47.3&#x2009;&#xb1;&#x2009;8.0 years) with long-COVID symptoms attributed to MCA were evaluated. Patients were treated with fexofenadine (180&#x2005;mg/day) and famotidine (40&#x2005;mg/day). Fatigue, brain fog, abdominal disorders, and increased heart rate were evaluated in treated and untreated patients at baseline and 20 days later.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Long-COVID symptoms disappeared completely in 29% of treated patients. There was a significant improvement in each of the considered symptoms (improved or disappeared) in all treated patients, and the improvement grade was significantly greater in treated patients compared to controls. No significant differences in the outcomes were observed in the controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our data confirm that histamine receptors blockade may be an effective target to successfully treat long-COVID. Our finding supports the underlying role of MCA in the pathophysiology of long-COVID.</AbstractText><CopyrightInformation>&#xa9; 2023 Salvucci, Codella, Coppola, Zacchei, Grassi, Anti, Nitisoara, Luzi and Gazzaruso.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salvucci</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Internal Medicine, Clinica Santa Rita del Gruppo Policlinico di Monza, Vercelli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Codella</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Applied Clinical Research (Ce.R.C.A.), Istituto Clinico Beato Matteo, Vigevano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zacchei</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiovascular and Metabolic Department, Ticinello Cardiovascular and Metabolic Centre, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassi</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiovascular and Metabolic Department, Ticinello Cardiovascular and Metabolic Centre, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anti</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Cardiovascular and Metabolic Department, Ticinello Cardiovascular and Metabolic Centre, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitisoara</LastName><ForeName>Nicolita</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Internal Medicine, Clinica Santa Rita del Gruppo Policlinico di Monza, Vercelli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luzi</LastName><ForeName>Livio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, IRCCS Multimedica, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazzaruso</LastName><ForeName>Carmine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antihistamines</Keyword><Keyword MajorTopicYN="N">histamine receptors</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">mast cell activation</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>4</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37529714</ArticleId><ArticleId IdType="pmc">PMC10388239</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2023.1202696</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gazzaruso C, Carlo Stella N, Mariani G, Tamburlini A, Garini P, Freddi E, et al. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19. Clin Rheumatol. (2020) 39:2475&#x2013;7. 10.1007/s10067-020-05239-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05239-5</ArticleId><ArticleId IdType="pmc">PMC7297548</ArticleId><ArticleId IdType="pubmed">32548723</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujia R, Ferro Y, Maurotti S, Khoory J, Gazzaruso C, Pujia A, et al. The effects of COVID-19 on the eating habits of children and adolescents in Italy: a pilot survey study. Nutrients. (2021) 13:2641. 10.3390/nu13082641</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13082641</ArticleId><ArticleId IdType="pmc">PMC8400531</ArticleId><ArticleId IdType="pubmed">34444801</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID-mechanisms, risk factors, and management. Br Med J. (2021) 374:n1648. 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer N, Meza-Torres B, Okusi C, Delanerolle G, Chapman M, Wang W, et al. Developing a long COVID phenotype for post-acute COVID-19 in a national primary care sentinel cohort: an observational retrospective database analysis. JMIR Public Health Surveill. (2022). 8:e36989. 10.2196/36989</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/36989</ArticleId><ArticleId IdType="pmc">PMC9374163</ArticleId><ArticleId IdType="pubmed">35861678</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. (2021) 32:e2315. 10.1002/rmv.2315</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2315</ArticleId><ArticleId IdType="pubmed">34888989</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. (2022) 54(1):1473&#x2013;87. 10.1080/07853890.2022.2076901</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. (2021) 74:103722. 10.1016/j.ebiom.2021.103722</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103722</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. Br Med J. (2020) 370:m3026. 10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). (2021) 53(10):737&#x2013;54. 10.1080/23744235.2021.1924397</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezi B, Chan L, Knapp JP, Karimi N, Alizadeh K, Mehrani Y, et al. Cytokine storm syndrome in SARS-CoV-2 infections:a functional role of mast cells. Cells. (2021) 10:1761. 10.3390/cells10071761</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10071761</ArticleId><ArticleId IdType="pmc">PMC8308097</ArticleId><ArticleId IdType="pubmed">34359931</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. (2020) 100:327&#x2013;32. 10.1016/j.ijid.2020.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in long-COVID. Int J Infect Dis. (2021) 112:217&#x2013;26. 10.1016/j.ijid.2021.09.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med. (2022) 70(1):61&#x2013;7. 10.1136/jim-2021-002051</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Alnima T, Mulder MMG, van Bussel BCT, Ten Cate H. COVID-19 coagulopathy: from pathogenesis to treatment. Acta Haematol. (2022) 145(3):282&#x2013;96. 10.1159/000522498</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000522498</ArticleId><ArticleId IdType="pmc">PMC9059042</ArticleId><ArticleId IdType="pubmed">35499460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaruso C, Paolozzi E, Valenti C, Brocchetta M, Naldani D, Grignani C, et al. Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity. Nutr Metab Cardiovasc Dis. (2020) 30(11):1914&#x2013;9. 10.1016/j.numecd.2020.07.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2020.07.040</ArticleId><ArticleId IdType="pmc">PMC7386389</ArticleId><ArticleId IdType="pubmed">32907762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. (2020) 39(7):2095&#x2013;7. 10.1007/s10067-020-05180-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05180-7</ArticleId><ArticleId IdType="pmc">PMC7251560</ArticleId><ArticleId IdType="pubmed">32462425</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollbracht C, Kraft K. Oxidative stress and hyper-inflammation as Major drivers of severe COVID-19 and long COVID: implications for the benefit of high-dose intravenous vitamin C. Front Pharmacol. (2022) 13:899198. 10.3389/fphar.2022.899198</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.899198</ArticleId><ArticleId IdType="pmc">PMC9100929</ArticleId><ArticleId IdType="pubmed">35571085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P, Calcaterra IL, Mosella M, Formisano R, D'Anna SE, Bachetti T, et al. Endothelial dysfunction in COVID-19: a unifying mechanism and a potential therapeutic target. Biomedicines. (2022) 10(4):812. 10.3390/biomedicines10040812</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10040812</ArticleId><ArticleId IdType="pmc">PMC9029464</ArticleId><ArticleId IdType="pubmed">35453563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Leber A, Jawad MY, Yu M, Lui LMW, Subramaniapillai M, et al. Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. Infect Dis (Lond). (2022) 54(7):467&#x2013;77. 10.1080/23744235.2022.2043560</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2022.2043560</ArticleId><ArticleId IdType="pmc">PMC8935463</ArticleId><ArticleId IdType="pubmed">35282780</ArticleId></ArticleIdList></Reference><Reference><Citation>San Mauro Martin I, Brachero S, Garicano Vilar E. Histamine intolerance and dietary management: a complete review. Allergol Immunopathol (Madr). (2016) 44(5):475&#x2013;83. 10.1016/j.aller.2016.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aller.2016.04.015</ArticleId><ArticleId IdType="pubmed">27590961</ArticleId></ArticleIdList></Reference><Reference><Citation>Luttrell MJ, Halliwill JR. The intriguing role of histamine in exercise responses. Exerc Sport Sci Rev. (2017) 45(1):16&#x2013;23. 10.1249/JES.0000000000000093</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/JES.0000000000000093</ArticleId><ArticleId IdType="pmc">PMC5161583</ArticleId><ArticleId IdType="pubmed">27741023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Greenhalgh T, Milne R, Delaney B. Are vaccines a potential treatment for long COVID? Br Med J. (2022) 377:o988. 10.1136/bmj.o988</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o988</ArticleId><ArticleId IdType="pubmed">35584848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolck UW, Haenisch B, Molderings GJ. Cardiovascular symptoms in patients with systemic mast cell activation disease. Transl Res. (2016) 174:23&#x2013;32.e1. 10.1016/j.trsl.2015.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2015.12.012</ArticleId><ArticleId IdType="pubmed">26775802</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi L, Salvucci F, Leuzzi S, Radaelli A, Calciati A, Valle F, et al. Cardiovascular reflex changes preceding episodes of vasovagal syncope in paediatric subjects. Clin Sci (Lond). (1996) 91(Suppl):25&#x2013;7. 10.1042/cs0910025supp</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs0910025supp</ArticleId><ArticleId IdType="pubmed">8813819</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>